Fusion Antibodies (LSE:FAB) Growth Rank: 1 (As of Sep. 13, 2026) — 67% Below Median

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LSE:FAB Fusion Antibodies PLC LSE:FAB
24 GF Score
Price £0.12
GF Value £0.04
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is Fusion Antibodies Growth Rank?

Fusion Antibodies LSE:FAB +2.17% 24 Growth Rank is 1 as of Sep. 13, 2026, which is 67% below its 10-year median of 3.00. GuruFocus rates LSE:FAB with a GF Score™ of 24/100 and a GF Value™ of £0.04 (Significantly Overvalued). The stock has 4 warning signs investors should review.

Fusion Antibodies has the Growth Rank of 1.

GuruFocus Growth Rank measures the growth of a company in terms of its revenue and profitability, rated on a scale from 1 to 10. Historically, the companies with the highest growth ranks performed the best over the long term. It is calculated using the following criteria:

1. 5-year revenue growth rate, the higher, the better.
2. 3-year revenue growth rate, the higher, the better.
3. 5-year EBITDA growth rate, the higher, the better.
4. The predictability of 5-year revenue. The most consistent it is, the higher the rank.

A higher score reflects a greater ability to drive business growth, with companies considered to have strong and sustainable expansion potential. Conversely, a lower score indicates challenges in achieving consistent growth and scalability.

GuruFocus found that the Growth Rank is the second of the two most-sensitive parameters among the five parameters checked. Please click GF Score to see more details on GF Score's 5 Key Aspects of Analysis.

Please note that we are using the five-year EBITDA growth rate as a parameter, so the company needs to have had positive growth over that time. The reason we use EBITDA instead of earnings per share is that with EBITDA, we can rank a lot more companies since a company may have positive EBITDA but negative EPS. Since we are looking at the growth here, EBITDA gives us a pretty clear picture about the growth in the company's business operations.

Fusion Antibodies Growth Rank Related Terms

LSE:FAB vs VRTX, REGN, MRNA: Growth Rank Comparison

For the Biotechnology subindustry, Fusion Antibodies's Growth Rank, along with its competitors' market caps and Growth Rank data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Fusion Antibodies Growth Rank vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Fusion Antibodies's Growth Rank distribution charts can be found below:

* The bar in red indicates where Fusion Antibodies's Growth Rank falls into.


LSE:FAB
24GF Score
Fusion Antibodies PLC LSE:FAB
Growth Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Growth Rank →
What does a Growth Rank of 1 mean?
Fusion Antibodies (LSE:FAB) has a Growth Rank of 1 as of Sep. 13, 2026. Growth Rank measures the growth of a company in terms of its revenue and profitability. View historical data on Fusion Antibodies and its competitors. This is 67% below median its historical median of 3.00. Over the past decade, Fusion Antibodies' Growth Rank has ranged from 1.00 to 9.00.
Is Fusion Antibodies' Growth Rank too high?
Fusion Antibodies' current Growth Rank of 1 is 67% below median its 10-year median of 3.00. Over the past 10 years, this metric has ranged from a low of 1.00 to a high of 9.00. Overall, Fusion Antibodies has a GF Score™ of 24/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Fusion Antibodies' Growth Rank compare to VRTX and REGN?
Fusion Antibodies' Growth Rank of 1 can be compared against companies in the Biotechnology industry. Historically, Fusion Antibodies' own Growth Rank has ranged from 1.00 to 9.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Growth Rank for a Biotechnology company?
A good Growth Rank depends on the Biotechnology industry context. However, Growth Rank should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Growth Rank mean?
A high Growth Rank can signal that a stock is expensive relative to its fundamentals. Growth Rank measures the growth of a company in terms of its revenue and profitability. View historical data on Fusion Antibodies and its competitors. Fusion Antibodies's current Growth Rank is 1, which is 67% below median its own 10-year median of 3.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Fusion Antibodies stock overvalued right now?
Based on GuruFocus' analysis, Fusion Antibodies (LSE:FAB) is currently considered Significantly Overvalued. The stock's GF Value™ is £0.04, compared to a current price of £0.12 — trading 193.8% above its estimated fair value. The current Growth Rank is 1, which is 67% below median its 10-year median of 3.00. Fusion Antibodies' overall GF Score™ is 24/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Growth Rank calculated?
Growth Rank is calculated from a company's financial statements. For Fusion Antibodies (LSE:FAB), the current Growth Rank is 1 as of Sep. 13, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Fusion Antibodies (LSE:FAB) Overvalued in 2026?

Based on GuruFocus' analysis, Fusion Antibodies stock appears to be overvalued. The current stock price of £0.12 is trading 193.8% above its estimated GF Value™ of £0.04. GuruFocus considers Fusion Antibodies to be Significantly Overvalued.

Key valuation signals for LSE:FAB:

  • Growth Rank: 1 (67% below median its 10-year median of 3.00)
  • GF Value™: £0.04 vs. price of £0.12 (193.8% above fair value)
  • GF Score™: 24/100 with 4 warning signs

No single metric tells the full story. See the LSE:FAB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Fusion Antibodies Business Description

Address 1 Springbank Road, Springbank Industrial Estate, Dunmurry, Northern Ireland, Belfast, GBR, BT17 0QL
Fusion Antibodies PLC is a Contract Research Organisation (CRO) providing antibody identification, engineering, and expression services for the discovery and development of antibodies for human and veterinary therapeutics, as well as for diagnostics. Its customers are pharmaceutical, biotech, veterinary, diagnostic, and life science research companies. The company's three core service areas include: Discovery (identification, screening, and sequencing of novel antibodies); Engineering (optimising the performance of antibodies); and Supply (production and purification of antibodies for further development). Geographically company generates the majority of its revenue from North America and the Rest of the World, followed by the United Kingdom and the Rest of Europe.
24GF Score

Get the complete analysis for LSE:FAB

Growth Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

£0.12
Price
£0.04
GF Value